Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL310 versus idursulfase in pediatric and young adult MPS II
NL-OMON59553Phase 3Active, not recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Nov 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of tividenofusp alfa and idursulfase in mucopolysaccharidosis type 2 (2 arms), sponsored by Denali Therapeutics Inc. Primary endpoints: Ratio to baseline in CSF heparan sulfate concentration and Change from baseline in Vineland-3. Started Nov 2022; status: active, not recruiting.
02
Drugs
tividenofusp alfaidursulfase
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on NL-OMON59553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59553.